Drug Development | Strategy & Clinical Trial Support
Leverage our seasoned drug development physicians to define your clinical strategy and manage your clinical trials.
Our clinical consulting team is led by seasoned pharmaceutical physicians with many years of drug development experience. Our consultants have extensive experience in planning and implementing clinical development programs, both for biotech and multinational companies, across a broad range of therapeutic areas including small molecules, biologics, and cell and gene therapies.
In addition to our core team, we draw from an expert network of over 500 life science professionals and functional specialists to support clients with the exact expertise their clinical development projects require, including drug development physicians, clinical operations specialists, and biostatisticians. Our consultants have made significant contributions to the development of launched products and have held global responsibilities for marketed medicines. Our team’s work spans most strategic aspects of clinical development as well as operational support on a selective basis. Although Alacrita is not a CRO, team members often manage CRO activities on behalf of clients, serving as an interface to ensure enrollment issues are managed proactively and that results are delivered as expected - something that can be crucial when a mismatch exists between the size of the CRO and the size of the client.
By engaging Alacrita, you can access high-caliber clinical trials professionals more rapidly than building an internal team, allowing early-stage enterprises to push forward efficiently and effectively with their drug’s development. Our large pharma clients frequently work engage Alacrita to augment existing teams during periods of rapid growth.
Drug development consulting services:
Clinical Strategy & Design
- developing target product profiles
- clinical development strategy & plans
- developing study synopses and trial protocols
- clinical trials benchmarking
- disease indication strategy and lifecycle management
- clinical operations support (CRO and site management)
- resolve recruitment issues
- providing medical support to for interacting with the FDA and European medicines agencies
- preparing dossiers and submissions
Interim Chief Medical Officer
Alacrita has a number of CMO-level clinical MDs in our expert network. We sometimes support our biotech clients with an interim Chief Medical Officer, for example during periods of extended search for a full time individual. These Alacrita consultants are capable of overseeing flagship clinical trials, guiding a portfolio of programs, providing leadership to junior medics in the organization, as well as representing the company with the board of directors, investors and regulatory authorities.
Case study: Defining a Clinical Strategy in Oncology
Challenge: A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic candidates, while allowing prospective partners to access the technology platform through selected R&D collaborations.Solution: Our oncology consultant created a detailed timeline and gap analysis for the company’s initial IND filing and Phase 0-l clinical trial launch, and conducted the following tasks.
reviewing relevant documents, including the technology, pre-existing corporate, scientific and clinical goals, and any preclinical data
holding interviews with key stakeholders including company founders, the CEO and the internal R&D team
reviewing potential target cancer indications and establishing up-to-date standards of care
reviewing relevant biomarkers to inform PK/PD activity and patient enrichment strategies
preparing a clinical development plan including prioritization of target indications, design of Phase 0-lla clinical trials and proposal for clinical trial investigators and sites
developing an interval-to-IND filing gap analysis.
- Our consultant presented to the board and was retained as an ongoing medical advisor to the company. Further case studies regarding the work Alacrita performs in clinical development are available here.
Recent Clinical Development Projects:
Interim Chief Medical Officer for fibrosis company
A well-capitalized, private biotech company with a drug discovery platform identified multiple first-in-class and best-in-class compounds targeting critical pathways widely involved in inflammatory and fibrotic diseases. As lead compounds progressed toward the development phase, the company was considering a broad spectrum of disorders as initial and follow on targets for therapy, including liver fibrotic disorders, idiopathic pulmonary fibrosis, renal fibrosis, and inflammatory bowel disease. The company desired a chief medical officer (CMO) with deep development experience in the broad area of fibrotic disease including liver, gastrointestinal, renal, and lung disease and organizational experience in the roles and responsibilities of a CMO.
Development support for first-in-class pediatric oncology drug
For a listed US biotech company with marketed products, Alacrita's pediatric oncologist consultant provided ongoing support with Phase I/II design, protocol development and medical oversight of a first-in-class oncology drug for a pediatric population. The drug mechanism has an immunotherapy modality and continues to be investigated in clinical trials.
Providing clinical and medical support in immuno-oncology
A leading immuno-oncology biotech company with a pipeline of novel, first-in-class clinical stage assets needed medical support for multiple clinical and medical affairs activities in Europe and the United States. Our support included providing advice and assistance with the following:
- clinical strategy and execution of the clinical development plans for the company’s drug candidates
- drug safety and pharmacovigilance
- fostering existing and future relationships with key opinion leaders, medical advisors and medical advisory boards.
We also assessed portfolio expansion opportunities and other corporate development activities from a clinical development and medical perspective.
Regulatory pathway for new wound care products
A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care and had mapped regulatory pathways relating to various classes of product. Having identified various paradigms for currently marketed products in the US including 510(k), Class III PMA, banked human tissue, Biologics License Application, and New Drug Application, the company needed to understand the corresponding regulatory pathways in Europe, and the regulatory requirements for bringing three of its products to market.
Independently reviewing clinical trial data
A small biopharmaceutical company asked us to provide an independent review of data from a recently completed clinical trial. We were to provide a summary report for the company’s management and board of directors. Due to an upcoming board meeting, this request had a tight deadline of only six days from the initial transfer of data to submission of the final report.
Chief Medical Officer support for listed biotech
A listed biotech company conducting Phase III clinical trials in an oncology indication needed Chief Medical Officer support for multiple clinical activities in Europe and the United States. We provided medical oversight of three ongoing clinical trials, in particular, providing medical oversight for a Phase I trial in preparation for a marketing application, a data and safety measurement board (DSMB) review of an ongoing Phase IIb clinical trial, and the launch of a Phase II clinical study in pancreatic cancer.
Recent White Papers:
Approximately 40% of recently approved cancer drugs have gone through one of four established FDA expedited programs. These treatments account for billions of dollars in sales and help create a thriving, industry-wide pipeline. The FDA has also recently approved the first New Drug Application (NDA) under one of its new pilot programs intended to speed cancer drug review, leading to optimism that these programs will also help speed delivery of more drugs to patients. But there has also been fresh criticism about results of the Accelerated Approval pathway and whether post-market trials support approval of most of these drugs. Will concerns about overuse lead to curtailment of these programs? Or do these concerns just reflect the age-old tension between getting drugs approved faster and knowing more about them before they are approved? Have criteria for what makes a good candidate for an expedited program changed? Here, we review the latest developments with insights and comments from Dr. William (Bill) Slichenmyer, a partner at Alacrita and an oncologist with more than 20 years of experience in the biopharma industry.